peptide vip FAQ

Aliquot the reconstituted peptide into single-use volumes (e.g., 50 µL per tube for one day's injections) and store at −80°C. Thaw one aliquot per day in the refrigerator 30 minutes before use and discard any unused volume after 24 hours. Do not refreeze. This protocol eliminates repeated freeze-thaw cycles on your stock solution, which fragment peptides and reduce titer over time. For a 28-day study with daily injections, you would aliquot 28 tubes from one reconstituted vial, keeping your working stock stable throughout the experimental timeline.

Request it explicitly before purchase, and if unavailable, source VIP from a different supplier. Mass spectrometry confirmation is not optional for research peptides. It verifies that the synthesized molecule matches the intended amino acid sequence and that no truncated or modified peptides are present above trace levels. Suppliers who claim proprietary synthesis methods prevent data sharing or offer only generic purity percentages are either using third-party manufacturers they cannot vouch for or are reselling material of unknown provenance. Legitimate research suppliers like Real Peptides provide ESI-MS traces specific to each production lot because this is standard quality assurance in peptide manufacturing, not a premium service.

Discard the vial and order a replacement. VIP loses 20–40% bioactivity after 12 hours at ambient temperature due to methionine oxidation and peptide bond hydrolysis. The degradation is irreversible and there is no reliable way to quantify remaining potency without receptor-binding assays. Using compromised peptide introduces a confounding variable that invalidates experimental results, particularly in dose-response studies where reduced activity could be misinterpreted as biological effect rather than material failure. The cost of replacing a single 2mg vial ($85–$120) is negligible compared to the cost of repeating an entire study with failed controls.

VIP for research is manufactured under good laboratory practice (GLP) standards, not GMP (good manufacturing practice), which applies to pharmaceutical production for clinical trials or marketed drugs. If your institutional biosafety or IACUC protocol mandates GMP, you will need to source VIP from a custom synthesis house that holds FDA registration as a contract manufacturer. These facilities charge significantly more ($300–$600 per vial) because they maintain cleanroom environments, validated production processes, and batch release testing that exceeds research-grade requirements. Most academic animal research protocols accept GLP-grade peptides; GMP is typically required only for IND-enabling toxicology studies or human pilot trials.

Plan for daily injections due to VIP's 1–2 minute half-life. No depot formulation exists for native VIP. Prepare aliquots of reconstituted peptide in single-use volumes to minimize freeze-thaw cycles, which denature the peptide. Consider using osmotic minipumps for continuous subcutaneous delivery if the protocol tolerates surgical implantation. This maintains stable plasma levels and reduces handling stress in animal models. Budget for higher peptide volumes than acute protocols require.

Verify storage temperature immediately. Exposure above 8°C causes progressive degradation even in lyophilized form, and reconstituted VIP degrades faster at room temperature. If the vial was stored correctly, the issue may be incomplete reconstitution. VIP requires gentle swirling, not vortexing, and full dissolution can take 5–10 minutes. Use bacteriostatic water, not saline, to prevent aggregation. If degradation is confirmed, discard the vial. Degraded peptide produces inconsistent results and cannot be rescued.

Oral bioavailability of native vasoactive intestinal peptide is essentially zero. The peptide is degraded by gastric acid and intestinal proteases before systemic absorption occurs. Intranasal delivery achieves limited CNS penetration through olfactory pathways, bypassing the blood-brain barrier partially, but systemic exposure remains minimal. Modified analogs with protease resistance or absorption enhancers can improve non-injectable delivery, but these are experimental and not commercially standardized. For reliable systemic or CNS effects, subcutaneous or intravenous administration remains necessary.

Administer VIP during the resolution phase rather than the initiation phase. Its efficacy shifts from prevention to repair. Post-peak VIP still promotes M2 macrophage polarization and Treg expansion, which accelerates inflammation resolution and tissue remodeling. Sepsis models show reduced efficacy when VIP is given after cytokine surge, but chronic inflammation models (arthritis, colitis) demonstrate benefit even when treatment begins after disease establishment. The therapeutic window narrows as the inflammatory cascade matures.